Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.64 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10811863 | 0.90 | PRMT5 (0.62) | PRMT5WDR77ACE2SMN1; SMN2CYP2D6 | |
| SCHEMBL13574574 | 0.88 | PRMT5 (0.65) | PRMT5WDR77ACE2SMN1; SMN2CYP2D6 | |
| SCHEMBL13574575 | 0.88 | PRMT5 (0.65) | PRMT5WDR77ACE2SMN1; SMN2CYP2D6 | |
| SCHEMBL10810924 | 0.88 | PRMT5 (0.53) | PRMT5WDR77 | |
| SCHEMBL10670904 | 0.85 | PRMT5 (0.53) | PRMT5WDR77ACE2SMN1; SMN2PRMT6 | |
| SCHEMBL6140348 | 0.84 | PRMT5 (0.60) | PRMT5WDR77ACE2SMN1; SMN2 | |
| SCHEMBL10735313 | 0.82 | PRMT6 (0.55) | PRMT5WDR77SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL10868032 | 0.82 | PRMT5 (0.56) | PRMT5WDR77ACE2SMN1; SMN2CYP2D6 | |
| SCHEMBL10504734 | 0.82 | PRMT5 (0.55) | PRMT5WDR77ACE2SMN1; SMN2PRMT6 | |
| SCHEMBL10669444 | 0.81 | PRMT5 (0.55) | PRMT5WDR77ACE2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5021431-A | H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion | HEUMANN PHARMA GMBH & CO. (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0199845-B1 | IMIDAZOLYLALKYLGUANIDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HEUMANN PHARMA GMBH & CO (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4727081-A | ANTIULCER AGENTS | LUDWIG HEUMANN & CO. GMBH (DE) | 1988-02-23 | — | — | US | disclosed |
| US-4656180-A | HISTAMINE-H2 RECEPTORS; ANTIULCER AGENTS | LUDWIG HEUMANN & CO., GMBH (DE) | 1987-04-07 | — | — | US | disclosed |
| EP-0071434-B1 | HETEROCYCLIC DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1987-01-28 | — | — | EP | disclosed |
| EP-0199845-A1 | Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them | HEUMANN PHARMA GMBH & CO (DE) | 1986-11-05 | — | — | EP | disclosed |
| US-4599346-A | ANTIULCER | LUDWIG HEUMANN & CO., GMBH (DE) | 1986-07-08 | — | — | US | disclosed |
| EP-0180754-A2 | 3,4-Diazole derivatives, process for their preparation and medicines containing these compounds | LUDWIG HEUMANN & CO GMBH (DE) | 1986-05-14 | — | — | EP | disclosed |
| US-4571394-A | HISTAMINE H2-ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1986-02-18 | — | — | US | disclosed |
| EP-0158789-A1 | Diamine derivatives, process for their preparation and medicines containing these compounds | LUDWIG HEUMANN & CO GMBH (DE) | 1985-10-23 | — | — | EP | disclosed |
| US-4518598-A | ANTIHISTAMINE | GLAXO GROUP LIMITED (GB) | 1985-05-21 | — | — | US | disclosed |
| US-4507296-A | Tetrazoles, pharmaceutical use and compositions | GLAXO GROUP LIMITED (GB) | 1985-03-26 | — | — | US | disclosed |
| EP-0132541-A2 | Propan-2-ol derivatives, process for their preparation and pharmaceutical compounds containing them | LUDWIG HEUMANN & CO GMBH (DE) | 1985-02-13 | — | — | EP | disclosed |
| US-4482552-A | ANTIHISTAMINES | GLAXO GROUP LIMITED (GB) | 1984-11-13 | — | — | US | disclosed |
| EP-0071434-A2 | Heterocyclic derivatives | GLAXO GROUP LIMITED (GB) | 1983-02-09 | — | — | EP | disclosed |